Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Solid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Malignant Neoplasmas 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Leukemia 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Injections 18Carboplatin 14Docetaxel 11pembrolizumab 8durvalumab 7Cisplatin 6linifanib 5Paclitaxel 5Nivolumab 5zimberelimab 4talazoparib 4olaparib 4Panobinostat 4Itraconazole 4Bevacizumab 4tremelimumab 3sintilimab 3depatuxizumab 3atezolizumab 3ST 1481 3S 1 (combination) 3Rifampin 3Pemetrexed 3Oxaliplatin 3Fluorouracil 3Everolimus 3Drug Therapy 3trifluridine tipiracil drug combination 2trametinib 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumors × ON 01910 × Clear all
NCT00861328 2017-06-23

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Traws Pharma, Inc.

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡